サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1423209

心臓バイオマーカー市場レポート：タイプ別、検査場所別、用途別、地域別、2024年～2032年

Cardiac Biomarkers Market Report by Type (Troponins, Myocardial Muscle Creatine Kinase, Myoglobin, Brain Natriuretic Peptide or NT-proBNP, Ischemia Modified Albumin, and Others), Location of Testing, Application, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 141 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
心臓バイオマーカー市場レポート：タイプ別、検査場所別、用途別、地域別、2024年～2032年
出版日: 2024年01月30日
発行: IMARC
ページ情報: 英文 141 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の心臓バイオマーカー市場規模は2023年に107億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに210億米ドルに達し、2024～2032年の成長率（CAGR）は7.6％を示すと予測しています。

心臓マーカーは心臓バイオマーカーとしても知られ、心臓にストレスがかかったり、筋肉が損傷したりすると血流に放出されます。これらのマーカーには、心筋トロポニン、クレアチンキナーゼ（CK）、虚血修飾アルブミン（IMA）、ミオグロビンなど、さまざまな種類の酵素、ホルモン、タンパク質が含まれます。これらのマーカーの測定や検査は、心臓虚血や急性冠症候群（ACS）などの心臓疾患の診断に役立ちます。現在、これらの疾患のリスクを判定するためのトリアージと診断システムは、心電図（ECG）と臨床経過に基づいています。しかし、これらのシステムは不十分であり、誤診や治療の遅れにつながる可能性があります。心臓マーカー検査は精度が高く、発症の初期段階で病態を特定できるため、世界中で普及しつつあります。これらのマーカーは、より高い精度でこれらの疾患の予後をモニタリングし、患者に最も効果的な治療を提供するのにも役立ちます。

心臓バイオマーカーの世界市場促進要因：

ここ数年、ACSに罹患する患者数が増加しており、これが世界レベルでの心臓マーカー検査の需要を生み出しています。この他にも、様々なCVDの早期診断の重要性に対する患者やヘルスケアプロバイダーの意識の高まりが、これらのマーカーに対する需要を促進しています。さらに、心臓バイオマーカー分野の先端技術を開発するために研究開発活動に投資している民間および公的機関が数多く存在します。例えば、高感度心筋トロポニンiの血液検査では、2回目の心臓発作のリスクが高い患者を特定できることが実証されています。さらに、バイオマーカー検査が提供する高い精度と迅速な結果は、手頃な価格の心臓ポイントオブケア検査の利用可能性と相まって、市場の成長に寄与している他の要因の一部です。

本レポートで扱う主な質問

  • 2023年の世界の心臓バイオマーカー市場規模は？
  • 2024～2032年の世界の心臓バイオマーカー市場の予想成長率は？
  • 世界の心臓バイオマーカー市場を牽引する主要因は何か？
  • COVID-19が世界の心臓バイオマーカー市場に与えた影響は？
  • 検査場所別世界の心臓バイオマーカー市場の内訳は？
  • 心臓バイオマーカーの世界市場の用途別区分は？
  • 心臓バイオマーカーの世界市場における主要地域は？
  • 心臓バイオマーカーの世界市場における主要企業/プレーヤーは？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 心臓バイオマーカーの世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場内訳：タイプ別
  • 市場内訳：検査場所別
  • 市場内訳：用途別
  • 市場内訳：地域別
  • 市場予測

第6章 市場内訳：タイプ別

  • トロポニン（Tとi）
    • 市場動向
    • 市場予測
  • 心筋クレアチンキナーゼ（CK-MB）
    • 市場動向
    • 市場予測
  • ミオグロビン
    • 市場動向
    • 市場予測
  • 脳性ナトリウム利尿ペプチド（BNP）またはNT-proBNP
    • 市場動向
    • 市場予測
  • 虚血修飾アルブミン（IMA）
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：検査場所別

  • ラボ検査
    • 市場動向
    • 市場予測
  • ポイントオブケア検査
    • 市場動向
    • 市場予測

第8章 市場内訳：用途別

  • 心筋梗塞
    • 市場動向
    • 市場予測
  • うっ血性心不全
    • 市場動向
    • 市場予測
  • 急性冠症候群
    • 市場動向
    • 市場予測
  • アテローム性動脈硬化症
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 市場動向
    • 市場予測
  • アジア太平洋
    • 市場動向
    • 市場予測
  • 欧州
    • 市場動向
    • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場予測
  • ラテンアメリカ
    • 市場動向
    • 市場予測

第10章 世界の心臓バイオマーカー産業：SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 世界の心臓バイオマーカー産業バリューチェーン分析

第12章 世界の心臓バイオマーカー産業ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 世界の心臓バイオマーカー産業価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Alere Inc.
    • Beckman Coulter
    • Becton, Dickinson And Co.
    • Biomerieux
    • Bio-Rad Laboratories
    • Randox Laboratories
    • Roche Diagnostics Corporation
    • Siemens Healthcare
    • Thermo Fisher Scientific
図表

List of Figures

  • Figure 1: Global: Cardiac Biomarkers Market: Major Drivers and Challenges
  • Figure 2: Global: Cardiac Biomarkers Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Cardiac Biomarkers Market: Breakup by Type (in %), 2023
  • Figure 4: Global: Cardiac Biomarkers Market: Breakup by Location of Testing (in %), 2023
  • Figure 5: Global: Cardiac Biomarkers Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Cardiac Biomarkers Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Cardiac Biomarkers Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 8: Global: Cardiac Biomarkers Industry: SWOT Analysis
  • Figure 9: Global: Cardiac Biomarkers Industry: Value Chain Analysis
  • Figure 10: Global: Cardiac Biomarkers Industry: Porter's Five Forces Analysis
  • Figure 11: Global: Cardiac Biomarkers (Troponins) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Cardiac Biomarkers (Troponins) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Cardiac Biomarkers (Myocardial Muscle Creatine Kinase) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Cardiac Biomarkers (Myocardial Muscle Creatine Kinase) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Cardiac Biomarkers (Myoglobin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Cardiac Biomarkers (Myoglobin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Cardiac Biomarkers (Brain Natriuretic Peptide) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Cardiac Biomarkers (Brain Natriuretic Peptide) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Cardiac Biomarkers (Ischemia Modified Albumin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Cardiac Biomarkers (Ischemia Modified Albumin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Cardiac Biomarkers (Other Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Cardiac Biomarkers (Other Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Cardiac Biomarkers (Laboratory Testing) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Cardiac Biomarkers (Laboratory Testing) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Cardiac Biomarkers (Point of Care Testing) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Cardiac Biomarkers (Point of Care Testing) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Cardiac Biomarkers (Myocardial Infarction) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Cardiac Biomarkers (Myocardial Infarction) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Cardiac Biomarkers (Congestive Heart Failure) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Cardiac Biomarkers (Congestive Heart Failure) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Cardiac Biomarkers (Acute Coronary Syndrome) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Cardiac Biomarkers (Acute Coronary Syndrome) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Cardiac Biomarkers (Atherosclerosis) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Cardiac Biomarkers (Atherosclerosis) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Cardiac Biomarkers (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Cardiac Biomarkers (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: North America: Cardiac Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: North America: Cardiac Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Asia Pacific: Cardiac Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Asia Pacific: Cardiac Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Europe: Cardiac Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Europe: Cardiac Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Middle East and Africa: Cardiac Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Middle East and Africa: Cardiac Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Latin America: Cardiac Biomarkers Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Latin America: Cardiac Biomarkers Market Forecast: Sales Value (in Million US$), 2024-2032

List of Tables

  • Table 1: Global: Cardiac Biomarkers Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Cardiac Biomarkers Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Cardiac Biomarkers Market Forecast: Breakup by Location of Testing (in Million US$), 2024-2032
  • Table 4: Global: Cardiac Biomarkers Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Cardiac Biomarkers Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Cardiac Biomarkers Market Structure
  • Table 7: Global: Cardiac Biomarkers Market: Key Players
目次
Product Code: SR112024A1178

Abstract

The global cardiac biomarkers market size reached US$ 10.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 21.0 Billion by 2032, exhibiting a growth rate (CAGR) of 7.6% during 2024-2032.

Cardiac markers, also known as cardiac biomarkers, are released into the bloodstream when the heart is stressed, or its muscles are damaged. These markers include different types of enzymes, hormones, and proteins, such as cardiac troponins, creatine kinase (CK), ischemia-modified albumin (IMA), and myoglobin. Measurement and testing of these markers can help in diagnosing heart conditions like cardiac ischemia and acute coronary syndrome (ACS). At present, the triage and diagnostic systems used for determining the risk of these conditions are based on electrocardiograms (ECGs) and clinical history. However, these systems are insufficient and can lead to misdiagnosis or delay in treatment. As cardiac marker testing offers higher accuracy and can identify the conditions in the early stages of presentation, they are gaining traction across the globe. These markers can also help in monitoring the prognosis of these condition with greater accuracy and providing the most effective treatment to the patients.

Global Cardiac Biomarkers Market Drivers:

Over the past few years, there has been a rise in the number of patients suffering from ACS which has created a demand for cardiac marker testing at a global level. Other than this, rising awareness among patients and healthcare providers about the importance of early diagnosis of various CVDs is driving the demand for these markers. In addition, there are numerous private and public organizations which are investing in R&D activities to develop advanced technologies in the field of cardiac biomarkers. For instance, blood tests for high-sensitivity cardiac troponin I have been demonstrated to identify patients who are at a higher risk of a second heart attack. Moreover, high accuracy and rapid results offered by biomarker testing, coupled with the availability of affordable cardiac point-of-care testing, are some of the other factors which are contributing to the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global cardiac biomarkers market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on type, location of testing, and application.

Breakup by Type:

Troponins (T and I)

Myocardial Muscle Creatine Kinase (CK-MB)

Myoglobin

Brain Natriuretic Peptide (BNPs) or NT-proBNP

Ischemia Modified Albumin (IMA)

Others

Based on the type, the market has been segmented into troponins (T and I), myocardial muscle creatine kinase (CK-MB), myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, ischemia modified albumin (IMA) and others.

Breakup by Location of Testing:

Laboratory Testing

Point of Care Testing

Based on the location of testing, the market has been segmented into laboratory testing and point of care testing. Laboratory testing currently accounts for a larger share.

Breakup by Application:

Myocardial Infarction

Congestive Heart Failure

Acute Coronary Syndrome

Atherosclerosis

Others

Based on the application, the market has been segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis and others. Myocardial infarction currently accounts for the highest share.

Regional Insights:

North America

Asia Pacific

Europe

Middle East and Africa

Latin America

Region-wise, the market has been segmented into North America, Asia Pacific, Europe, Middle East and Africa, and Latin America. Amongst these, North America is the biggest market, accounting for majority of the global share.

Competitive Landscape:

The report has also analyzed the competitive landscape of the market with some of the key players being Abbott Laboratories, Alere Inc., Beckman Coulter, Becton, Dickinson And Co., Biomerieux, Bio-Rad Laboratories, Randox Laboratories, Roche Diagnostics Corporation, Siemens Healthcare and Thermo Fisher Scientific.

Key Questions Answered in This Report

  • 1. What was the size of the global cardiac biomarkers market in 2023?
  • 2. What is the expected growth rate of the global cardiac biomarkers market during 2024-2032?
  • 3. What are the key factors driving the global cardiac biomarkers market?
  • 4. What has been the impact of COVID-19 on the global cardiac biomarkers market?
  • 5. What is the breakup of the global cardiac biomarkers market based on the location of testing?
  • 6. What is the breakup of the global cardiac biomarkers market based on the application?
  • 7. What are the key regions in the global cardiac biomarkers market?
  • 8. Who are the key companies/players in the global cardiac biomarkers market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cardiac Biomarkers Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Type
  • 5.5 Market Breakup by Location of Testing
  • 5.6 Market Breakup by Application
  • 5.7 Market Breakup by Region
  • 5.8 Market Forecast

6 Market Breakup by Type

  • 6.1 Troponins (T and I)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Myocardial Muscle Creatine Kinase (CK-MB)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Myoglobin
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Brain Natriuretic Peptide (BNPs) or NT-proBNP
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Ischemia Modified Albumin (IMA)
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Location of Testing

  • 7.1 Laboratory Testing
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Point of Care Testing
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Myocardial Infarction
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Congestive Heart Failure
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Acute Coronary Syndrome
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Atherosclerosis
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Middle East and Africa
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Latin America
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Global Cardiac Biomarkers Industry: SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Global Cardiac Biomarkers Industry: Value Chain Analysis

12 Global Cardiac Biomarkers Industry: Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Global Cardiac Biomarkers Industry: Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
    • 14.3.2 Alere Inc.
    • 14.3.3 Beckman Coulter
    • 14.3.4 Becton, Dickinson And Co.
    • 14.3.5 Biomerieux
    • 14.3.6 Bio-Rad Laboratories
    • 14.3.7 Randox Laboratories
    • 14.3.8 Roche Diagnostics Corporation
    • 14.3.9 Siemens Healthcare
    • 14.3.10 Thermo Fisher Scientific